Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/cid/ciaa344 http://scihub22266oqcxt.onion/10.1093/cid/ciaa344 32221519!7184337!32221519     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32221519.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Clin+Infect+Dis 2020 ; 71 (16): 2027-2034 Nephropedia Template TP {{tp|p=32221519|t=2020. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019 |pdf=|usr=}}{{32221519}} gab.com Text Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019 JO: Clin Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32221519 #FOAvip BACKGROUND: The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patients remains largely unknown, and the clinical value of antibody testing has not been fully demonstrated. METHODS: 173 patients with SARS-CoV-2 infection were enrolled. Their serial plasma samples (n = 535) collected during hospitalization were tested for total antibodies (Ab), IgM, and IgG against SARS-CoV-2. The dynamics of antibodies with disease progress were analyzed. RESULTS: Among 173 patients, the seroconversion rates for Ab, IgM, and IgG were 93.1%, 82.7%, and 64.7%, respectively. The reason for the negative antibody findings in 12 patients might be due to the lack of blood samples at the later stage of illness. The median seroconversion times for Ab, IgM, and then IgG were days 11, 12, and 4, respectively. The presence of antibodies was <40% among patients within 1 week of onset, and rapidly increased to 100.0% (Ab), 94.3% (IgM), and 79.8% (IgG) by day 15 after onset. In contrast, RNA detectability decreased from 66.7% (58/87) in samples collected before day 7 to 45.5% (25/55) during days 15-39. Combining RNA and antibody detection significantly improved the sensitivity of pathogenic diagnosis for COVID-19 (P < .001), even in the early phase of 1 week from onset (P = .007). Moreover, a higher titer of Ab was independently associated with a worse clinical classification (P = .006). CONCLUSIONS: Antibody detection offers vital clinical information during the course of SARS-CoV-2 infection. The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients. Twit Text FOAVip Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019 ????Clin Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32221519 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32221519 #FOAvip English Wikipedia <ref>{{Cite pmid|32221519}}</ref> Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019 #MMPMID32221519 Zhao J; Yuan Q; Wang H; Liu W; Liao X; Su Y; Wang X; Yuan J; Li T; Li J; Qian S; Hong C; Wang F; Liu Y; Wang Z; He Q; Li Z; He B; Zhang T; Fu Y; Ge S; Liu L; Zhang J; Xia N; Zhang Z Clin Infect Dis 2020[Nov]; 71 (16): 2027-2034 PMID32221519show ga BACKGROUND: The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patients remains largely unknown, and the clinical value of antibody testing has not been fully demonstrated. METHODS: 173 patients with SARS-CoV-2 infection were enrolled. Their serial plasma samples (n = 535) collected during hospitalization were tested for total antibodies (Ab), IgM, and IgG against SARS-CoV-2. The dynamics of antibodies with disease progress were analyzed. RESULTS: Among 173 patients, the seroconversion rates for Ab, IgM, and IgG were 93.1%, 82.7%, and 64.7%, respectively. The reason for the negative antibody findings in 12 patients might be due to the lack of blood samples at the later stage of illness. The median seroconversion times for Ab, IgM, and then IgG were days 11, 12, and 4, respectively. The presence of antibodies was <40% among patients within 1 week of onset, and rapidly increased to 100.0% (Ab), 94.3% (IgM), and 79.8% (IgG) by day 15 after onset. In contrast, RNA detectability decreased from 66.7% (58/87) in samples collected before day 7 to 45.5% (25/55) during days 15-39. Combining RNA and antibody detection significantly improved the sensitivity of pathogenic diagnosis for COVID-19 (P < .001), even in the early phase of 1 week from onset (P = .007). Moreover, a higher titer of Ab was independently associated with a worse clinical classification (P = .006). CONCLUSIONS: Antibody detection offers vital clinical information during the course of SARS-CoV-2 infection. The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients. |Adult[MESH] |Aged[MESH] |Antibodies, Viral/metabolism[MESH] |Antibody Formation/physiology[MESH] |COVID-19/*immunology/*virology[MESH] |Enzyme-Linked Immunosorbent Assay[MESH] |Female[MESH] |Humans[MESH] |Immunoglobulin G/metabolism[MESH] |Immunoglobulin M/metabolism[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |SARS-CoV-2/*immunology/*pathogenicity[MESH]Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Di(epmc).pdf DeepDyve Pubget Overpricing